Cytokinetics shows hand in high stakes rivalry with BMS' Camzyos

Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug Camzyos, and a new analysis gives the first shot at an apples-to-apples comparison with late-phase data showing improvements in exercise capacity among patients.